Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974577 | 1.00 | GBA1 (0.47) | GBA1PTGS1PTGS2SLC6A2SLC6A4 | |
| SCHEMBL5974091 | 1.00 | GBA1 (0.47) | GBA1PTGS1PTGS2SLC6A2SLC6A4 | |
| SCHEMBL6001188 | 1.00 | GBA1 (0.47) | GBA1PTGS1PTGS2SLC6A2SLC6A4 | |
| SCHEMBL5974087 | 1.00 | GBA1 (0.47) | GBA1PTGS1PTGS2SLC6A2SLC6A4 | |
| SCHEMBL5974321 | 0.83 | GBA1 (0.68) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL5205480 | 0.83 | GBA1 (0.68) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL6001919 | 0.83 | GBA1 (0.68) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL5973809 | 0.83 | GBA1 (0.68) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL6001914 | 0.83 | GBA1 (0.68) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL6856976 | 0.82 | GBA1 (0.71) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GBA1 2386/4885PTGS1 418/4885PTGS2 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.